Karyopharm Therapeutics (KPTI)
NASDAQ:KPTI
Holding KPTI?
Track your performance easily

Karyopharm Therapeutics (KPTI) Income Statement

1,132 Followers

Karyopharm Therapeutics Income Statement

Last quarter (Q3 2024), Karyopharm Therapeutics's total revenue was $38.78M, an increase of 7.70% from the same quarter last year. In Q3, Karyopharm Therapeutics's net income was $-32.07M. See Karyopharm Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 148.44M$ 146.03M$ 157.07M$ 209.82M$ 108.08M$ 40.89M
Cost of Revenue
$ 6.16M$ 4.94M$ 5.21M$ 3.40M$ 2.71M-
Gross Profit
$ 142.28M$ 141.09M$ 151.86M$ 206.42M$ 105.38M$ 40.89M
Operating Expense
$ 269.47M$ 270.63M$ 294.06M$ 308.09M$ 279.94M$ 230.17M
Operating Income
$ -125.97M$ -129.54M$ -142.20M$ -98.27M$ -171.85M$ -189.28M
Net Non Operating Interest Income Expense
$ -12.60M$ -12.88M$ -22.64M$ -25.46M$ -24.32M$ -10.22M
Other Income Expense
$ -63.49M$ -356.00K$ -83.00K$ 85.00K$ -206.00K$ 50.00K
Pretax Income
$ -87.18M$ -142.78M$ -164.92M$ -123.82M$ -195.96M$ -199.55M
Tax Provision
$ 296.00K$ 323.00K$ 369.00K$ 268.00K$ 309.00K$ 40.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -87.48M$ -143.10M$ -165.29M$ -124.09M$ -196.27M$ -199.59M
Basic EPS
$ -0.79$ -1.25$ -2.02$ -1.65--
Diluted EPS
$ -1.14$ -1.25$ -2.02$ -1.65$ -2.72$ -3.22
Basic Average Shares
$ 351.40M$ 114.22M$ 81.87M$ 75.22M$ 72.04K$ 61.96M
Diluted Average Shares
$ 384.80M$ 114.22M$ 81.87M$ 75.22M$ 72.04K$ 61.96M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 275.63M$ 275.57M$ 299.28M$ 311.49M$ 279.63M$ 230.17M
Net Income From Continuing And Discontinued Operation
$ -87.48M$ -143.10M$ -165.29M$ -124.09M$ -196.27M$ -199.59M
Normalized Income
$ -8.10M-----
Interest Expense
------
EBIT
$ -66.14M$ -118.95M$ -139.93M$ -97.77M$ -168.82M$ -183.90M
EBITDA
$ -60.87M$ -117.61M$ -139.31M$ -96.98M$ -167.85M$ -177.09M
Currency in USD

Karyopharm Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis